Skip to content

Cannabis for anxiety

Studies whose primary subject is both Cannabis and Anxiety, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 18 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, Anxiety, generalized anxiety disorder, then ranked by relevance.

The evidence is mixed and depends heavily on the cannabinoid: pure CBD shows a tentative anxiolytic signal in small experimental studies and reviews, whereas THC reliably increases acute anxiety in controlled human dosing, and whole-plant or THC-dominant cannabis tends to raise state anxiety. Observational data complicate this, with some surveys linking cannabis use to anxiety reduction and others linking both THC and CBD vaping to more anxiety symptoms in adolescents. The main caveats are small samples, short follow-up, mostly healthy or lightly exposed volunteers, and a near absence of long-term trials in diagnosed anxiety disorders.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 18 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing 2009 RCT (double-blind, placebo-controlled crossover) 15 Mixed THC increased anxiety and autonomic arousal to fearful faces, while CBD showed a trend toward reduced anxiety and dampened limbic activation.
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug 2006 review Supports Animal and healthy-volunteer studies suggest an anxiolytic-like effect of CBD, and CBD reduced THC-induced anxiety and psychotic-like symptoms.
Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol 2009 RCT 15 Opposes THC increased anxiety, intoxication, sedation and psychotic symptoms, whereas CBD had no significant effect on these measures.
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review 2020 systematic review Mixed Evidence for cannabinoids in psychiatry is nascent and insufficient to recommend them, though isolated studies give tentative support for CBD in social anxiety.
Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol 2009 RCT 15 Supports CBD, but not THC, disrupted amygdala-to-anterior-cingulate forward connectivity during fearful-face processing, proposed as a correlate of its anxiolytic properties.
Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties 2020 systematic review Mixed Acute CBD reduced anxiety without anxiogenic effects at higher doses, while human clinical studies commonly show an anxiogenic response to THC, and epidemiological data tend to support anxiolytic effects of cannabis consumption.
Mitigation of post‐traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence 2012 review Supports Argues that cannabis products may reduce PTSD symptoms including anxiety and flashbacks via endocannabinoid effects on stress-sensitive brain regions, based largely on a single case and preclinical evidence.
Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors 2018 experimental study (animal) Mixed Intra-prefrontal THC produced anxiogenic effects, while intra-prefrontal CBD did not affect anxiety but blocked THC's anxiogenic properties.
Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis 2022 observational cohort 233475 Opposes People with a pre-existing anxiety diagnosis had higher risk of cannabis-associated psychotic symptoms requiring emergency treatment (risk ratio 2.92).
Effects of Chronic Exposure to Low-Dose delta-9-Tetrahydrocannabinol in Adolescence and Adulthood on Serotonin/Norepinephrine Neurotransmission and Emotional Behavior 2020 RCT (animal) Opposes Chronic low-dose THC in adolescence and adulthood produced an anxious phenotype in the elevated plus maze and reduced serotonergic activity.
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis 2022 RCT (placebo-controlled, within-subjects) 26 Mixed THC and THC/CBD both raised state anxiety versus placebo, but THC/CBD produced less anxiety than THC alone, and CBD's counteracting effect was absent in those with high baseline anxiety.
Acute Ultra Low Dose THC Attenuates Anxiety-Like Behavior in a Mouse Model for Major-Depressive Disorder 2026 preclinical animal study Supports Acute ultra-low-dose THC (0.002 mg/kg) reduced anxiety-like behavior, with Elmod1 and glucocorticoid-related mRNAs implicated as mediators.
Physical Activity Level Moderates Cannabis-Associated Reductions in Negative Affect in Anxious Individuals. 2026 secondary analysis of an RCT 178 Supports Negative affect decreased over four weeks in all cannabis groups (CBD-dominant, THC-dominant, THC+CBD), with physical activity moderating the decline only in the THC-dominant group.
Beyond the Diagnostic Binary: A Translational Use of the Research Domain Criteria to Improve the Measurement of Anxiety in the Context of Cannabis Use 2026 mixed methods study 30 Mixed Both medical and recreational consumers showed clinically significant anxiety symptoms, and the authors argue a transdiagnostic framework is needed to capture when cannabis induces versus reduces anxiety.
Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders 2026 qualitative descriptive study 9 Supports Participants reported perceived improvements in sleep, emotional regulation and daily functioning, describing cannabis as a tool for managing rather than eliminating anxiety.
Long-term effects of adolescent THC exposure on anxiety-like behavior and cognitive function in male rats 2026 RCT (animal) Opposes Adolescent THC exposure (5 mg/kg/day) produced anxiety-like behavior in the elevated plus maze but not the light-dark test, alongside impaired novelty preference.
Cannabis vaping and mental health: The association of Δ-9-tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms-Findings from the United States National Youth Tobacco Survey (2021-2023). 2026 observational (cross-sectional survey) 69899 Opposes Relative to non-vapers, adolescents vaping CBD only or THC only had higher odds of anxiety symptoms, and exclusive CBD vaping was associated with higher odds than exclusive THC vaping.
Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice. 2026 experimental study (animal) Opposes THC induced anxiety-like behavior, with adenosinergic and cannabinoidergic receptor systems interacting in this effect.

Points of agreement

  • Controlled human dosing consistently shows THC increases acute anxiety, intoxication and arousal.
  • CBD alone shows a tentative anxiolytic signal in small experimental studies and reviews, without anxiogenic effects at higher doses.
  • Co-administered CBD appears to blunt THC-induced anxiety in some experimental settings.
  • Several reviews and observational studies report that people use cannabis to reduce anxiety symptoms.

Conflicts

  • Epidemiological and self-report data often suggest anxiolytic effects of cannabis, while controlled clinical dosing more often shows THC-induced anxiety.
  • One controlled trial found CBD had no significant effect on anxiety, while others report anxiolytic trends or reduced arousal.
  • Adolescent survey data link CBD vaping to higher anxiety odds, opposite to the anxiolytic direction seen in adult experimental work.
  • Animal studies disagree by dose and route: ultra-low-dose THC reduced anxiety-like behavior, whereas higher chronic or intra-prefrontal THC increased it.

Gaps

  • Very few long-term or adequately powered trials in people with diagnosed anxiety disorders.
  • Durability of any anxiolytic benefit beyond weeks to months is largely unstudied.
  • Dose-response for CBD and THC in humans is poorly characterized.
  • Most controlled human studies use small samples of healthy, minimally cannabis-exposed volunteers, limiting generalizability.
  • Blinding integrity and expectancy effects in cannabis trials are rarely addressed.
  • Little research on whole-plant products, routes of administration, and interactions with baseline anxiety severity.
Browse these studies in the library

Common questions

What does the research agree on about cannabis for anxiety?
  • Controlled human dosing consistently shows THC increases acute anxiety, intoxication and arousal.
  • CBD alone shows a tentative anxiolytic signal in small experimental studies and reviews, without anxiogenic effects at higher doses.
  • Co-administered CBD appears to blunt THC-induced anxiety in some experimental settings.
  • Several reviews and observational studies report that people use cannabis to reduce anxiety symptoms.
Where do studies on cannabis for anxiety conflict?
  • Epidemiological and self-report data often suggest anxiolytic effects of cannabis, while controlled clinical dosing more often shows THC-induced anxiety.
  • One controlled trial found CBD had no significant effect on anxiety, while others report anxiolytic trends or reduced arousal.
  • Adolescent survey data link CBD vaping to higher anxiety odds, opposite to the anxiolytic direction seen in adult experimental work.
  • Animal studies disagree by dose and route: ultra-low-dose THC reduced anxiety-like behavior, whereas higher chronic or intra-prefrontal THC increased it.
What is still unknown about cannabis for anxiety?
  • Very few long-term or adequately powered trials in people with diagnosed anxiety disorders.
  • Durability of any anxiolytic benefit beyond weeks to months is largely unstudied.
  • Dose-response for CBD and THC in humans is poorly characterized.
  • Most controlled human studies use small samples of healthy, minimally cannabis-exposed volunteers, limiting generalizability.
  • Blinding integrity and expectancy effects in cannabis trials are rarely addressed.
  • Little research on whole-plant products, routes of administration, and interactions with baseline anxiety severity.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Cannabis for anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Cannabis for anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

78 articles · 18 from the last two years · 600,086 participants across 36 studies reporting sample size

Common study designs

review 9 systematic review 7 experimental study 4 observational cohort 4 randomized controlled trial 11

Research volume by year

Compare topics →

75 studies whose primary subject is cannabis for anxiety since 2003

Studies about cannabis for anxiety per year, 2003 to 2026, peaking at 10 in 2023 Bar chart: one bar per year, taller where more studies were published that year. 0 5 10 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about cannabis for anxiety per year, 2003 to 2026, peaking at 10 in 2023
Year Studies
2003 1
2004 1
2005 0
2006 1
2007 0
2008 0
2009 3
2010 2
2011 0
2012 1
2013 0
2014 3
2015 2
2016 0
2017 5
2018 5
2019 7
2020 8
2021 2
2022 4
2023 10
2024 2
2025 8
2026 10

Research

Synthesize the evidence →

Acute Ultra Low Dose THC Attenuates Anxiety-Like Behavior in a Mouse Model for Major-Depressive Disorder

Journal of Molecular Neuroscience October 12, 2026 Meitar Grad, Hadas Volkov, Noam Shomron

Abstract Major depressive disorder (MDD) is a prevalent psychiatric disorder, and is a leading cause of disability worldwide. Current treatments for MDD entail many side effects, and include a lag until the onset of therapeutic effects. The current hypotheses as for the etiology of MDD revolve around the monoamine hypothesis and the plasticity and neurodegeneration hypothesis. According to the...

DOI: 10.1007/s12031-026-02597-8 (opens in new tab) Full text (opens in new tab)

Physical Activity Level Moderates Cannabis-Associated Reductions in Negative Affect in Anxious Individuals.

Clinical Therapeutics September 2026 Jonathon K. Lisano, Luiza Rosa, Greg Giordano et al.

Emerging research indicates that the use of cannabis products, particularly those higher in cannabidiol (CBD), may be anxiolytic. Physical activity is another modality observed to have anxiolytic effects. Despite evidence of cannabis and physical activity being paired together, there is limited research on the possible synergistic effects of physical activity and cannabis use on reductions in...

DOI: 10.1016/j.clinthera.2026.02.007 (opens in new tab) Full text (opens in new tab) Anxiety CBD Cannabidiol Cannabis +2

Beyond the Diagnostic Binary: A Translational Use of the Research Domain Criteria to Improve the Measurement of Anxiety in the Context of Cannabis Use

Healthcare August 1, 2026 Nicole Ennis, Katie Kloss, Alyssa Flores

Introduction: Epidemiological data indicate that over half of people who consume cannabis report anxiety reduction as a reason for use. Anxiety is frequently cited as a primary motivation for cannabis use among both medical and recreational consumers. The lifetime prevalence of anxiety disorders in the United States is approximately 34% with more recent data suggesting that the figure may be as...

DOI: 10.3390/healthcare14152333 (opens in new tab)

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms

Journal of Drug Issues July 1, 2026 Haley M Hummel, Alexia N Obrochta, David C. R. Kerr et al.

Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use...

DOI: 10.1177/00220426261466154 (opens in new tab) Psilocybin Anxiety Cannabis Hallucinogen +8

Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders

International Journal of Clinical Pharmacy June 9, 2026 Leah Roberts, Craig Cumming, C. Budgeon et al.

Anxiety disorders are among the most prevalent and disabling mental health conditions and are associated with impairments in quality of life (QoL). Previous studies have examined medicinal cannabis for anxiety and QoL using short-term follow-up or cross-sectional surveys. However, there is little longitudinal qualitative research examining how patients experience QoL changes. To explore the...

DOI: 10.1007/s11096-026-02176-2 (opens in new tab) Full text (opens in new tab)

Long-term effects of adolescent THC exposure on anxiety-like behavior and cognitive function in male rats

Psychopharmacology April 23, 2026 Josephine Sena Lumor, Henriette Nyberg, Elisabeth Nerem et al.

Abstract Rationale As cannabis legalization and decriminalization have expanded, it is increasingly perceived as a low-risk substance. Concurrently, the potency of cannabis products and the number of young adults seeking treatment for cannabis use disorder have risen markedly. A growing body of research links early onset, frequent use, and high potency cannabis products to a range of adverse...

DOI: 10.1007/s00213-026-07067-y (opens in new tab)

Cannabis vaping and mental health: The association of Δ-9-tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms-Findings from the United States National Youth Tobacco Survey (2021-2023).

Addiction March 2026 Jack Chung, Daniel Stjepanović, Brandon Cheng et al.

Cannabis use is associated with psychiatric comorbidities, and the use of elta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Observational data were drawn from three years of the nationally...

DOI: 10.1111/add.70218 (opens in new tab) Full text (opens in new tab) Anxiety Depression Cannabis use Mental health +1

Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users

European Neuropsychopharmacology February 12, 2026 José Carlos Bouso, Óscar Andión, Sabela Fondevila Estévez et al.

The increasing interest in the therapeutic potential of psychedelics and cannabis underscores the need to understand their long-term neuropsychological and personality effects. This cross-sectional study compared regular users of ayahuasca (n = 69), cannabis (n = 56), and non-substance users (n = 94) on a battery of neuropsychological tasks and psychological questionnaires. Participants were...

DOI: 10.1016/j.euroneuro.2026.112782 (opens in new tab) Cannabis Ayahuasca Anxiety Clinical psychology +11

Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice.

Brain and Behavior February 1, 2026 Burçin Ün, Zeki Akarsakarya, Özlem Yorulmaz Özü et al.

Previous studies have suggested that adenosinergic system in the central nervous system may play a role in both behavioral changes and the physiopathology induced by Δ9-tetrahydrocannabinol (THC), and this is thought to be mediated by adenosine A2A receptors (A2ARs). However, the contribution of the adenosinergic system to the anxiety-like behaviors in response to THC in mice is not well...

DOI: 10.1002/brb3.71126 (opens in new tab) Full text (opens in new tab) Tetrahydrocannabinol Adenosine a2a receptors Anxiety‐like behaviors Hippocampus

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

DOI: 10.52778/ppt20260001 (opens in new tab) Serotonergic MDMA Addiction Cannabis +16

Clinical trials

All cannabis for anxiety trials →